Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007

ease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation triggered by gluten. There are no currently marketed pharmaceutical products for this disorder and the current treatment for Celiac is complete elimination of gluten from the diet.

Celiac disease is largely under-diagnosed although recent advances in diagnostics have improved diagnosis dramatically. After screening, it is thought that the incidence is approximately 1% (1) in the western world.

About AT-1001:

AT1001 is a novel peptide that inhibits intestinal paracellular permeability by inhibiting stimulus-induced cytoskeletal rearrangement in epithelial cells that leads to the disassembly of tight junctions. It is currently under investigation in a multi-centre, double blind, placebo controlled Phase 2 dose ranging study to evaluate its safety, tolerability and efficacy in 140 Celiac subjects during gluten challenge.

Notes to Editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under The Private Securities Litigation R
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... The Wisconsin Alumni Research Foundation ( WARF ) and ... nutritional supplement manufacturer today with willful and deliberate patent ... , ,The French company, Arkopharma , and its ... the suit when they continued to sell certain products ...
... - The growing body of university research under development beyond ... grow at an even faster pace as the result of ... System presidents and the Wisconsin Alumni Research Foundation. ... for researchers at UW System schools. The focus, however, extends ...
... Lee Dreyfus made a few waves when he suggested ... blue-eyed Arabs of the Upper Midwest" by selling fresh ... many of his ideas, often delivered off-the-cuff to mask ... Dreyfus proposal simultaneously stirred the imagination and set off ...
Cached Biology Technology:WARF sues French company over patent violation 2WiSys to distribute $1 million in research funds 2WiSys to distribute $1 million in research funds 3WiSys to distribute $1 million in research funds 4Fresh water could be a deep economic wellspring for Wisconsin 2Fresh water could be a deep economic wellspring for Wisconsin 3
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
(Date:10/14/2014)... kind of stem cell that can become either a liver ... to a study published today in the journal Stem ... contradicts current theory on how organs arise from cell layers ... and future treatment for, liver cancer., Thanks to stem cells, ... made up of more than 200 cell types. The original, ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... known PSA blood test for prostate cancer in men may ... breast cancer, the most common form of cancer in women ... ACS journal Analytical Chemistry . Chien Chou and ... test also is a potential biomarker of breast cancer in ...
... is available in German and Spanish . ... Chile pose a higher threat to its neighbour, Argentina, than ... of Concepcin in Chile and the Helmholtz Centre for Environmental ... particular, 22 non-native species which occur in Chile on connecting ...
... has shown that light is the key to getting our ... exploring the resynchronisation mechanism in insects has discovered a molecule ... University of London looked at the impact of light on ... flies. They identified a novel molecule, QUASIMODO (QSM), which was ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3Newly discovered molecule essential to resetting 'body clocks' 2
Canine Serum...
NORMAL DONOR DONKEY SERUM...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Biology Products: